Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2026)

Zenas BioPharma's Share-based Compensation history runs 4 years deep, the most recent figure standing at $80.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 1390.9% year-over-year to $80.3 million in Q1 2026; TTM through Mar 2026 was $80.3 million, a 1349.72% increase from a year earlier, with the FY2025 full-year figure at $83.7 million, up 12.5% from the prior year.
• Share-based Compensation improved to $80.3 million in Q1 2026 per ZBIO's latest filing, from $7.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $81.2 million in Q3 2025 and bottomed at -$4.2 million in Q4 2024.
• The 4-year median for Share-based Compensation is $2.8 million (2024), against an average of $16.7 million.
• Across the five-year window, Share-based Compensation tumbled 472.33% in 2024 and surged 2756.14% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $1.1 million in 2023, then tumbled by 472.33% to -$4.2 million in 2024, then jumped by 279.37% to $7.6 million in 2025, then surged by 959.37% to $80.3 million in 2026.
• Per Business Quant, the three latest ZBIO Share-based Compensation figures stand at $80.3 million (Q1 2026), $7.6 million (Q4 2025), and $81.2 million (Q3 2025).